Nan Fung Group Holdings Ltd Takes Position in Kymera Therapeutics, Inc. $KYMR

Nan Fung Group Holdings Ltd acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 30,875 shares of the company’s stock, valued at approximately $3,540,436. Kymera Therapeutics accounts for approximately 0.0% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 11th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in KYMR. BlackRock Inc. bought a new stake in Kymera Therapeutics during the second quarter valued at about $635,067,000. Baker BROS. Advisors LP boosted its holdings in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the period.

Kymera Therapeutics Price Performance

KYMR traded down $2.46 during trading on Friday, hitting $117.77. 204,638 shares of the stock traded hands, compared to its average volume of 735,355. The firm has a 50-day moving average of $112.23 and a 200 day moving average of $93.44. Kymera Therapeutics, Inc. has a 12-month low of $39.84 and a 12-month high of $130.05. The firm has a market capitalization of $9.79 billion, a P/E ratio of -36.35 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same period last year, the company earned ($0.95) EPS. The company’s revenue for the quarter was up 465.2% on a year-over-year basis. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -3.78 EPS for the current fiscal year.

Analyst Ratings Changes

KYMR has been the topic of several analyst reports. Citigroup reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Thursday, August 6th. Mizuho raised their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Finally, Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $127.17.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the sale, the director directly owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce Booth sold 467,878 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director owned 472,267 shares in the company, valued at approximately $52,086,327.43. This trade represents a 49.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 3,587,629 shares of company stock valued at $386,183,782. 15.98% of the stock is currently owned by company insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.